AI Article Synopsis
- The study aimed to assess the effectiveness of postoperative tegafur-uracil on overall survival in patients with stage I adenocarcinoma, building on previous clinical trials.
- It utilized a retrospective analysis of a multi-institutional database from 2014 to 2016, comparing survival outcomes of patients treated with and without tegafur-uracil.
- The results indicated that the survival benefits of tegafur-uracil were similar to those observed in randomized trials, potentially enhancing outcomes particularly in patients aged 45 to 75 years.
Article Abstract
Purpose: The effect of postoperative tegafur-uracil on overall survival (OS) after resection of stage I adenocarcinoma has been shown in clinical trials. The purpose of this study was to investigate whether findings from randomized trials of adjuvant tegafur-uracil are reproducible in a real-world setting.
Methods: A retrospective cohort study was performed using a multi-institutional database that included all patients who underwent complete resection of pathological stage I adenocarcinoma between 2014 and 2016. Survival outcomes for patients managed with and without tegafur-uracil were analyzed using the Kaplan-Meier method and a Cox proportional hazards model for the whole patient cohort and in a selected cohort based on eligibility criteria of a previous randomized trial. Propensity score matching was used to adjust for confounding effects.
Results: After propensity score matching, the hazard ratios for OS were 0.57 (95% confidence interval (CI) 0.29-1.14, P = 0.11) in the whole cohort and 0.69 (95% CI 0.32-1.50, P = 0.35) in the selected cohort.
Conclusions: The effects of tegafur-uracil in this retrospective study appear to be consistent with those found in randomized clinical trials. These effects may be maximized in patients aged from 45 to 75 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-022-02546-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study.
Jpn J Clin Oncol
November 2024
Division of Thoracic Surgery, Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Article Synopsis
- The study examines the potential competition between adjuvant osimertinib and the current standard treatment, oral tegafur/uracil (UFT), for early-stage lung adenocarcinoma in Japan, particularly focusing on the impact of EGFR mutations on patient outcomes.
- Researchers analyzed data from 1812 patients with stage I adenocarcinoma to compare 5-year disease-free survival (DFS) rates based on their EGFR mutation status and whether they received UFT treatment.
- Results show that while the DFS rates varied by treatment and mutation status, adjuvant UFT did not provide a significant survival advantage, particularly in patients with EGFR mutations, indicating the need for alternative therapies in this group.
A 73-year-old woman underwent a descending colectomy for descending colon cancer. The tumor was graded as pStage Ⅲb(pT3[SS], pN1b, pM0, Cur A), according to the 9th edition of the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Postoperative treatment of adjuvant chemotherapy comprised oral tegafur/uracil and Leucovorin for 6 months with no evident recurrence.
View Article and Find Full Text PDFEffect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
Ann Thorac Cardiovasc Surg
January 2024
Department of General Thoracic Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan.
Purpose: Tegafur-uracil (UFT) is the standard postoperative adjuvant therapy for stage IB lung adenocarcinoma (LUAD) in Japan. This study aimed to determine whether UFT is effective in stage IB LUAD with and without epidermal growth factor receptor (EGFR) mutations.
Methods: This retrospective study included 169 patients with stage IB LUAD who underwent complete resection at our department between 2010 and 2021.
Unusual presentation of penile giant condyloma acuminatum with spontaneous prepuce perforation: A case report.
World J Clin Cases
October 2023
Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114024, Taiwan.
Background: Giant condyloma acuminatum (GCA) is an uncommon condition affecting the anogenital area.
Case Summary: Here, we report an 88-year-old male patient who presented with a 5-year history of a progressive appearance of multiple cauliflower-like warts over his penile shaft, pubis region, and groin as well as urine leakage along the distal penile shaft. Physical examination revealed an ulcerative skin perforation with pus discharge under the distal prepuce base, which was initially suspected to be a urethral fistula.
Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
Clin Lung Cancer
January 2024
Department of Thoracic Surgery, Kyoto University, Sakyo-ku Kyoto, Kyoto, Japan.
Article Synopsis
- The study investigates the effectiveness of adjuvant chemotherapy (ACT) for elderly patients (aged 75 and older) with completely resected non-small-cell lung cancer (NSCLC) at p-stage II-IIIA, addressing a gap in previous research that focused on younger patients.
- Data was analyzed from a nationwide registry of 812 patients who underwent lobectomy in 2010, with findings indicating that those who received ACT had significantly better overall survival compared to those who did not.
- The study concludes that ACT should be considered for elderly patients with completely resected NSCLC, reinforcing the idea that age alone should not determine treatment options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!